Marker Therapeutics, Inc. (MRKR)
- Previous Close
4.4800 - Open
4.4000 - Bid 3.1200 x 200
- Ask 5.4900 x 200
- Day's Range
4.2900 - 4.4212 - 52 Week Range
0.9000 - 9.6800 - Volume
12,576 - Avg. Volume
18,484 - Market Cap (intraday)
38.193M - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5900 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.50
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
markertherapeutics.comRecent News: MRKR
Performance Overview: MRKR
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRKR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRKR
Valuation Measures
Market Cap
38.19M
Enterprise Value
20.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.72
Enterprise Value/Revenue
3.41
Enterprise Value/EBITDA
-1.38
Financial Highlights
Profitability and Income Statement
Profit Margin
-248.76%
Return on Assets (ttm)
-35.36%
Return on Equity (ttm)
-83.47%
Revenue (ttm)
3.31M
Net Income Avi to Common (ttm)
-14.05M
Diluted EPS (ttm)
-1.5900
Balance Sheet and Cash Flow
Total Cash (mrq)
15.11M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-10.14M